<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03402945</url>
  </required_header>
  <id_info>
    <org_study_id>PICS-PREVENA V1_20171106</org_study_id>
    <nct_id>NCT03402945</nct_id>
  </id_info>
  <brief_title>Prevention of Infections in Cardiac Surgery (PICS) Prevena Study</brief_title>
  <acronym>PICS-Prevena</acronym>
  <official_title>A Cluster-randomized Factorial Crossover Trial, Comparing Antibiotic Mono-prophylaxis With Cefazolin vs. Dual-prophylaxis With Cefazolin Plus Vancomycin and Conventional Wound Dressing vs. Prevena Negative-pressure Wound Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This vanguard study will be conducted at two study sites in Canada. It is a cluster
      randomized trial to test a combination of two antibiotics for antibiotic prophylaxis as
      compared to routine prophylaxis with one single antibiotic, and to test a negative-pressure
      wound management system (Prevena) versus standard wound dressing to reduce chest wound
      infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the routine use of antibiotics before and after cardiac surgery, infections of the
      chest wound remain a common life threatening complication of heart surgery that is
      preventable. Antibiotic prophylaxis is well accepted to be the cornerstone of prevention for
      these infections. The best choice of antibiotic prophylaxis in patients undergoing open heart
      surgery is, however, unclear. A large number of relevant pathogens are not covered by the
      primarily recommended antibiotic for prophylaxis, and there is a large variability in the
      antibiotics physicians use in practice and a lack of evidence supporting these choices.
      Appropriate management of the wound is probably also highly relevant in terms of infection
      prevention; however, there is a lack of strong evidence guiding the choice of wound
      management strategies as a means to reduce surgical site infection. The proposed study will
      test whether dual antibiotic prophylaxis is superior to single-agent prophylaxis with
      cefazolin, and shed light on whether or not modern negative-pressure wound management
      technology lower the risk of sternal surgical site infections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>1) cefazolin prophylaxis plus Prevena*(*diabetic and/or obese patients (BMI &gt;30kg/m2)) 2) cefazolin and vancomycin prophylaxis plus Prevena*(*diabetic and/or obese patients (BMI &gt;30kg/m2)), 3) cefazolin prophylaxis plus standard wound dressing, 4) cefazolin and vancomycin prophylaxis plus standard wound dressing.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded adjudication of the s-SSIs will be performed by a committee consisting of three members.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to the wound management system</measure>
    <time_frame>Prevena or standard wound dressing applied after surgery as per protocol, assessed up to 90 days after surgery</time_frame>
    <description>goal is &gt;90%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to the antibiotic regimen</measure>
    <time_frame>Cefazolin: within an hour of surgery; one intra-operative dose at 4 hours after the first dose or upon wound closure (whatever comes first); two post-operative doses q8h. Vancomycin: initially intravenously; second dose 12 hrs after the first dose.</time_frame>
    <description>goal is &gt;90%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Loss of follow-up</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>goal is &lt;10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deep incisional and organ/space sternal-surgical site infection (s-SSI)</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>using standardized CDC/NHSN (Centre for Disease Control and Prevention/National Healthcare Safety Network) definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound dehiscence</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>using standardized CDC/NHSN (Centre for Disease Control and Prevention/National Healthcare Safety Network) definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C. difficile infection</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>laboratory confirmed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in patients with an active infection</measure>
    <time_frame>up to 90 days after surgery</time_frame>
    <description>using standardized CDC/NHSN (Centre for Disease Control and Prevention/National Healthcare Safety Network) definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU (Intensive Care Unit) and hospital stay</measure>
    <time_frame>Length of ICU - from date of surgery to initial ICU discharge date, assessed up to 90 days after surgery. Hospital Stay - date of surgery to date of hospital discharge, assessed up to 90 days after surgery.</time_frame>
    <description>length</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on day 7</measure>
    <time_frame>Pain at Day 7 (+/- 1 day)</time_frame>
    <description>Visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>within 7 days of surgery</time_frame>
    <description>Based on serum creatinine, following Acute Kidney Injury Network definition</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Surgical Site Infections</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.
Prevena will be applied to all diabetic and/or obese patients (BMI &gt;30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.
Prevena will be applied to all diabetic and/or obese patients (BMI &gt;30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.
Standard wound dressing: non-negative wound dressing as standard of care at the study site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.
Standard wound dressing: non-negative wound dressing as standard of care at the study site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena</intervention_name>
    <description>Negative-Pressure Wound Management System</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>antibiotic</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>antibiotic</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>Vancocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard wound dressing</intervention_name>
    <description>Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - â‰¥18 years of age undergoing open-heart surgery (sternotomy, including minimally-invasive
        sternotomies)

        Exclusion Criteria:

          -  On systemic antibiotics or with an active bacterial infection at the time of surgery

          -  Patients previously enrolled in this trial

          -  Patients known to be colonized with Methicillin-resistant S. aureus (MRSA)(unethical
             not to administer glycopeptides), beta-lactam or vancomycin allergy precluding the use
             of cefazolin or vancomycin, respectively, or to silver precluding the use of Prevena

          -  Participation in other studies that may interfere with this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominik Mertz, MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Hospital and Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Copland, CCRA</last_name>
    <phone>905-527-4322</phone>
    <phone_ext>40368</phone_ext>
    <email>prevena@phri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Copland</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>40368</phone_ext>
      <email>prevena@phri.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Lamy, MD,MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre &amp; Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Fox</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>35031</phone_ext>
      <email>stephanie.fox@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Mackenzie Quantz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Connolly SJ, Philippon F, Longtin Y, Casanova A, Birnie DH, Exner DV, Dorian P, Prakash R, Alings M, Krahn AD. Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT). Can J Cardiol. 2013 Jun;29(6):652-8. doi: 10.1016/j.cjca.2013.01.020. Review. Erratum in: Can J Cardiol. 2013 Jul;29(7):889.</citation>
    <PMID>23702356</PMID>
  </reference>
  <reference>
    <citation>Mertz D, Whitlock R, Kokoszka AY, Smith SW, Carignan A, Rehan M, Jaffer IH, Alsagheir A, Loeb M. Routine Surveillance Versus Independent Assessment by an Outcome Adjudication Committee in Assessing Patients for Sternal Surgical Site Infections After Cardiac Surgery. Infect Control Hosp Epidemiol. 2016 May;37(5):600-2. doi: 10.1017/ice.2015.347. Epub 2016 Jan 19.</citation>
    <PMID>26782707</PMID>
  </reference>
  <reference>
    <citation>Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR; Society of Thoracic Surgeons. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration. Ann Thorac Surg. 2006 Jan;81(1):397-404.</citation>
    <PMID>16368422</PMID>
  </reference>
  <results_reference>
    <citation>Filsoufi F, Castillo JG, Rahmanian PB, Broumand SR, Silvay G, Carpentier A, Adams DH. Epidemiology of deep sternal wound infection in cardiac surgery. J Cardiothorac Vasc Anesth. 2009 Aug;23(4):488-94. doi: 10.1053/j.jvca.2009.02.007. Epub 2009 Apr 19.</citation>
    <PMID>19376733</PMID>
  </results_reference>
  <results_reference>
    <citation>Lador A, Nasir H, Mansur N, Sharoni E, Biderman P, Leibovici L, Paul M. Antibiotic prophylaxis in cardiac surgery: systematic review and meta-analysis. J Antimicrob Chemother. 2012 Mar;67(3):541-50. doi: 10.1093/jac/dkr470. Epub 2011 Nov 13. Review.</citation>
    <PMID>22083832</PMID>
  </results_reference>
  <results_reference>
    <citation>Mertz D, Johnstone J, Loeb M. Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis. Ann Surg. 2011 Jul;254(1):48-54. doi: 10.1097/SLA.0b013e318214b7e4. Review.</citation>
    <PMID>21412147</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>negative pressure wound management system</keyword>
  <keyword>open-heart surgery</keyword>
  <keyword>antibiotic prophylaxis</keyword>
  <keyword>surgical site infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

